(E/Z) -Zotiraciclib (hydrochloride)

(E/Z) -Zotiraciclib ((E/Z) -TG02) is an orally active inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z) -Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1321626-25-8]

Product Name Alternative

(E/Z) -TG02 (hydrochloride) ; (E/Z) -SB1317 (hydrochloride)

UNSPSC

12352005

Target

CDK; FLT3; JAK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/e-z-zotiraciclib-hydrochloride.html

Purity

99.90

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2.Cl

Molecular Formula

C23H25ClN4O

Molecular Weight

408.92

References & Citations

[1]William AD, et al. Discovery of kinase spectrum selective macrocycle (16E) -14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1 (2,6) .1 (8,12) ]heptacosa-1 (25),2 (26),3,5,8 (27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012;55 (1) :169-196. |[2]Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6 (1) :33-42.